Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
PHASE3
The purpose of this study is to evaluate the safety and immunogenicity of B...
Metagenomic Analysis of the Pharynx in High Risk Partners
N/A
The Neisseria gonorrhoea (NG) epidemic in England is at the highest level i...
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2026-07-14
Trial ID
NCT07671014
Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.
PHASE3
Assess the safety and immunogenicity of a 3-dose schedule (at 2, 4, 6 month...